Novavax Inc.’s experimental Covid-19 vaccine produced high levels of antibodies against the novel coronavirus, according to initial data from a small, early-stage clinical trial, sending the company’s shares up 10%.
The University of Oxford suggested that the end of 2020 is possible for the availability of a Covid-19 vaccine candidate being developed with AstraZeneca, but expressed caution about the timeline.
German biotech firm BioNTech and U.S. drugmaker Pfizer reported additional data showing their experimental Covid-19 vaccine was safe and induced an immune response in patients.
A Covid-19 vaccine developed by CanSino Biologics and China’s military research unit was shown to be safe and induced immune response in most of the recipients, researchers said.
According to data published in The New England Journal of Medicine, a Phase I trial of Moderna’s mRNA vaccine against SARS-CoV-2 demonstrated promising safety and immune response in all patients involved in the study.
Russian scientists hailed the results of their first clinical trial of a potential coronavirus vaccine, saying it had been proved safe and that volunteers had developed an immune response.
Moderna Inc.’s experimental vaccine for Covid-19 showed mRNA-1273 was safe and provoked immune responses in all 45 healthy volunteers in an ongoing early-stage study, U.S. researchers reported.
Developing an ‘Inverse Vaccine’ for Type 1 Diabetes Published: July 14, 2020 By Chelsea Weidman Burke BioSpace What do you get when you mix certain immune cells with vitamin D and a disease-provoking molecule? An innovative new vaccine for type 1 diabetes. “We are trying to educate the immune system to teach it what […]
With rising numbers of COVID-19 infections and as the fight against the novel coronavirus continues, Novavax received $1.6 billion in federal funding to support the clinical development of the company’s vaccine candidate NVX‑CoV2373.
Novavax entered into a deal with contract drugmaker AGC Biologics to manufacture the company’s experimental COVID-19 vaccine.